R. McClure

发表

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.

D. Gilliland, R. Levine, D. Gilliland, 2006, Blood.

JAK2V617F mutation in essential thrombocythaemia: clinical associations and long‐term prognostic relevance

M. Wadleigh, A. Tefferi, Stephanie J. Lee, 2005, British journal of haematology.

Constitutive Fas Ligand Gene Transcription in Sertoli Cells Is Regulated By Sp1*

C. Payá, R. McClure, C. Heppelmann, 1999, The Journal of Biological Chemistry.

A new method to extract nuclei from paraffin-embedded tissue to study lymphomas using interphase fluorescence in situ hybridization.

G. Dewald, R. McClure, E. Remstein, 2002, The American journal of pathology.

Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms: A Report of the Association for Molecular Pathology.

Annette S. Kim, Robyn L. Temple-Smolkin, R. McClure, 2018, The Journal of molecular diagnostics : JMD.

Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors.

D. Larson, A. Tefferi, A. Wolanskyj, 2006, Mayo Clinic proceedings.

syndrome in both "atypical" myeloproliferative disorders and the myelodysplastic The JAK2 V617F activating tyrosine kinase mutation is an infrequent event

D. Steensma, H. Powell, A. Tefferi, 2013 .

myelodysplastic syndromes event in both ''atypical'' myeloproliferative disorders and The JAK2 V617F activating tyrosine kinase mutation is an infrequent

R. Levine, D. Gilliland, D. Steensma, 2013 .

Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders

R. McClure, T. Lasho, M. Mai, 2006, Leukemia.

The JAK2 V617F Mutation is Absent in Patients with Erythrocytosis Due to High Oxygen Affinity Hemoglobin Variants

J. Hoyer, R. McClure, M. Mai, 2006, Hemoglobin.

The JAK 2 V 617 F activating tyrosine kinase mutation is an infrequent event in both “ atypical ” myeloproliferative disorders and myelodysplastic syndromes

R. Levine, D. Gilliland, D. Steensma, 2005 .

Clonal relationship between precursor B-cell acute lymphoblastic leukemia and histiocytic sarcoma: a case report and discussion in the context of similar cases.

A. Feldman, J. Khoury, R. Ketterling, 2010, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

A longitudinal study of the JAK2(V617F) mutation in myelofibrosis with myeloid metaplasia: analysis at two time points.

R. Mesa, H. Powell, A. Tefferi, 2006, Haematologica.

JAK2V617F and leukemic transformation in myelofibrosis with myeloid metaplasia

R. Mesa, H. Powell, A. Tefferi, 2006 .

Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications.

C. James, G. Ahmann, R. Fonseca, 2007, Blood.

Novel FISH probes designed to detect IGK-MYC and IGL-MYC rearrangements in B-cell lineage malignancy identify a new breakpoint cluster region designated BVR2

A. Dogan, R. Ketterling, R. McClure, 2006, Leukemia.

Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time

R. Levine, R. Mesa, A. Tefferi, 2006, British journal of haematology.

Mucosal CD30-positive T-cell lymphoproliferations of the head and neck show a clinicopathologic spectrum similar to cutaneous CD30-positive T-cell lymphoproliferative disorders

A. Feldman, A. Dogan, R. McClure, 2012, Modern Pathology.

JAK2 V617F Mutation in Essential Thrombocythemia: Clinical Associations and Long-Term Prognostic Relevance.

D. Gilliland, M. Wadleigh, A. Tefferi, 2005 .

A phase-2 trial of low-dose pomalidomide in myelofibrosis

R. Mesa, A. Tefferi, W. Hogan, 2011, Leukemia.

Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders.

A. Tefferi, M. Lacy, T. Lasho, 2006, Blood.

Rate of EGFR mutation testing for patients with nonsquamous non-small-cell lung cancer with implementation of reflex testing by pathologists.

R. McClure, R. El-Maraghi, P. Cheema, 2017, Current oncology.

Histiocytes containing immunoglobulin crystals in the urine of a patient with IgA κ plasmacytoma of the bladder

B. Leibovich, T. Sebo, R. McClure, 2004, Diagnostic cytopathology.

Microgranular variant of acute promyelocytic leukemia with normal conventional cytogenetics, negative PML/RARA FISH and positive PML/RARA transcripts by RT-PCR.

R. Ketterling, R. McClure, S. Abhyankar, 2011, Cancer genetics.

IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms

A. Tefferi, T. Lasho, A. Pardanani, 2010, Leukemia.

Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

H. Kantarjian, S. Verstovsek, R. Mesa, 2006, Blood.

Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q)

A. Tefferi, R. Ketterling, A. Pardanani, 2010, Leukemia.

MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count.

D. Steensma, A. Tefferi, T. Lasho, 2006, Haematologica.

Isolated isochromosome 17q: a distinct type of mixed myeloproliferative disorder/myelodysplastic syndrome with an aggressive clinical course

G. Dewald, J. Hoyer, R. McClure, 1999, British journal of haematology.

Agnogenic Myeloid Metaplasia with Pleural Extramedullary Leukemic Transformation

A. Tefferi, K. Lim, R. McClure, 2004, Leukemia & lymphoma.

20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis

R. Mesa, A. Tefferi, T. Lasho, 2008, European journal of haematology.

clinical implications Tumor suppressor p16 methylation in multiple myeloma: biological and

C. James, G. Ahmann, M. Oken, 2013 .

Lenalidomide (CC-5013) Treatment for Anemia Associated with Myelofibrosis with Myeloid Metaplasia.

D. Steensma, R. Mesa, A. Tefferi, 2005 .

WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults.

A. Tefferi, T. Lasho, A. Pardanani, 2010, Blood.

Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies.

A. Tefferi, T. Lasho, A. Pardanani, 2009, Blood.

tyrosine kinase inhibitor response, and kinase domain mutation analysis : prevalence, morphology, BCR-ABL Chronic myeloid leukemia with p190

A. Tefferi, W. Hogan, M. Litzow, 2011 .

Chronic myeloid leukemia with p190BCR-ABL: prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis.

A. Tefferi, W. Hogan, M. Litzow, 2009, Blood.

JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia.

R. Mesa, H. Powell, A. Tefferi, 2006, Leukemia research.

HIV and plasmablastic lymphoma manifesting in sinus, testicles, and bones: A further expansion of the disease spectrum

S. Schichman, P. Mehta, R. McClure, 2004, American journal of hematology.

Clonal mast cell disease not meeting WHO criteria for diagnosis of mastocytosis: clinicopathologic features and comparison with indolent mastocytosis

A. Tefferi, J. Butterfield, A. Pardanani, 2013, Leukemia.